CLINICAL TRIAL SUMMARY

MDACC Study No:ID01-710 (clinicaltrials.gov NCT No: NCT00429494)
Title:PHASE II STUDY OF GnRH ANALOGUE FOR OVARIAN FUNCTION PRESERVATION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS
Principal Investigator:Naoto Ueno
Treatment Agent:Leuprolide Acetate
Study Status:Terminated
Study Description:The goals of this clinical research study are to save the fertility of the
patients who have hematopoietic stem cell transplantation and to prevent them
from suffering the side effects of early menopause. Hematopoietic stem cells
are early or parent cells that are taken from the blood. Researchers also want
to see if the study drug, leuprolide, is able to save ovarian function of the
patients when they are receiving high dose chemotherapy and/or radiation
therapy.

Hide details for General InformationGeneral Information

Disease Group:Other Supportive
Phase of Study:Phase II
Treatment Agents:Leuprolide Acetate
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:3-4 weeks in-patient hospitalization for the hematopoietic stem cell
transplantation
Supported By:N/A
Return Visit:Allogeneic: After discharged, clinic visit 2-3/wks up to 100 days after
transplant, then monthly up to 1 yr.
Autologous: After discharged, clinic visit 2-3/wks up to 30 days after
transplant, then every 1-2 mos up to 1 yr.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-794-5780
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults